NIAID workshop: What is a robust PK-PD package?

Dear All:

The ~150 of us who gathered in Washington yesterday and today for the NIAID’s PK-PD workshop enjoyed a very rich conversation. It’s really hard to capture the full debate, but here is a brief slide set and as well a written summary of the meeting that provide the main points. More materials can be found online at this link.

The heart of the workshop was an extended debate about the nature of a “robust PK-PD package.” We also had a good discussion of what PK-PD both can and can’t do. See the slides, but the critical material is also excerpted below my signature.

Given the intrinsic variability in all biological assays, a core message was that PD target estimates may differ substantially by method and by lab.  A lot of the discussion focused on  ways to manage this variability. Building substantial depth by testing multiple isolates in multiple models and by use of benchmark (internal control) compounds were all discussed as ways to build confidence around an estimate.

Overall, I see PK-PD as a field that continues to evolve rapidly. You definitely need an expert at your side (and it was great to have all the PK-PD gurus in the room!) but it is possible to find solid ground via careful work.

Many thanks to team NIAID for making this event happen with a special thanks to Tina Guina and Ann Eakin for their proactive leadership!

All best wishes and safe travels, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust
Follow me on Twitter: @JohnRex_NewAbx

Text from two of the slides

What is robust dose selection?

  • “Robust” should reduce risk. What reduces risk?
    • Standards:
      • Use benchmark compounds as internal controls. We do this implicitly within classes – being explicit about this is helpful
      • Isolates: Consider the use of standard (QC-like) PD isolates
    • Orthogonal data:
      • Test a range of isolates & models.
      • Chose them to explore relevant variation
    • Buffer your P3 study vs. patient-level PK variation
      • Select dose to give maximum exposure within tox limits
      • When all you have is HV data, anticipate greater variance in patients
      • Get PK in suitably diverse patient settings as early as possible
    • Exposure at the site matters: Keep site PK in mind … is plasma a good correlate or do you need to go deeper (e.g., ELF)?

What PK-PD can / cannot do

  • Can
    • Early: Derisk dose-selection
    • Mid: Enable programs to happen at all in settings where clinical data are limited
    • Late: Help with labeling questions about dosing and PK in special pops, pediatrics, drug-drug interactions, etc.
    • Late: Provide support to breakpoint determination
  • Cannot (necessarily)
    • Speed the program: PK-PD is often iterative
    • Make overall program smaller: You may well need to spend time exploring / confirming PK in relevant patient settings

Share

Fireside Chat with BARDA’s Branch Chief for Antimicrobials

Note: Be sure to take advantage of the BARDA Industry Day(s) event that occurs Monday-Tuesday of this coming week … see newsletter and forward calendar for details. Dear All, In what could be called Part 2 of Excellent 2023 ASM/ESCMID Talks (read the newsletter on Jen Cohen’s talk on how manufacturing underpins both access and

Japan Pulls for Pandemic Preparedness: Nikkei FT Conference

Dear All, As we discussed in the 5 Nov 2023 “Pulling for Pandemic Preparedness” newsletter, AMR is a global threat: resistance in one part of the world can suddenly appear in your hospital. As an example of that sort of threat, Jason Gale’s 30 Oct 2023 newsletter entitled “Untreatable Typhoid Should Make You Worry About Poop”

Pulling for Pandemic Preparedness

Dear All, This evening I’d like to bring together several relatively recent reports and note how all of them focus in one way or another on Pulling for Pandemic Preparedness … perhaps we can call this the Rule of 3 Ps. And as an aside, I’ll note that I learned the Rule of 4 Ps

PACE: A new £30m fund for AMR innovation

Dear All, Exciting additional news merits two newsletters in one day! I’ll keep it brief and quote directly from the website: “Innovate UK, LifeArc, and Medicines Discovery Catapult (MDC) have joined forces to create PACE (Pathways to Antimicrobial Clinical Efficacy), a £30 million initiative supporting early-stage innovation against antimicrobial resistance (AMR) to save lives. PACE has today (19 October 2023) announced

Scroll to Top